AF710B (aka ANAVEX 3-71), is a brain-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications. 

AF710B is effective against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and has also demonstrated beneficial effects on neuroinflammation and mitochondrial dysfunctions1

Similarly, AF710B lon​g-term treatment reverted the cognitive deficits associated with advanced Alzheimer-like amyloid neuropathology in McGill-R-Thy1-APP transgenic rats2. These effects were accompanied by reductions in amyloid pathology and markers of neuroinflammation and increases in amyloid cerebrospinal fluid clearance and levels of a synaptic marker. ​​

With long-lasting disease-modifying properties at low dose, AF710B is a promising novel therapeutic agent for treating Alzheimer's and other related diseases. 

AF710B (ANAVEX 3-71) and its patents were licensed for further development. U.S. FDA Granted Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia. 

  1. AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease. Fisher ABezprozvanny IWu LRyskamp DABar-Ner NNatan NBrandeis RElkon HNahum VGershonov ELaFerla FMMedeiros RNeurodegener Dis. 2016;16(1-2):95-110; 

  1. AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease. Hall H, Iulita MF, Gubert P, Flores Aguilar L, Ducatenzeiler A, Fisher A, Cuello AC Alzheimer's & Dementia. 2017 Dec 29. pii: S1552-5260(17)33851-7. doi: 10.1016/j.jalz.2017.11.009. [Epub ahead of print]


Patents: ​

A. Fisher, N. Bar-Ner, Victoria Nahum Bicyclic heterocyclic spiro compounds, US 8,673,931 B2 Mar. 18, 2014.The composition and method Patent covers AF710B for treating Alzheimer’s disease, type 2 diabetes and insulin resistance.  The Patent has a term that expires no earlier than April 29, 2030.

A. Fisher, N. Bar-Ner, Victoria Nahum Bicyclic heterocyclic spiro compounds, US 9,034,891 B2 May. 19, 2015.